Clinical Trials on High-risk Myelodysplastic Syndrome (MDS)
Total 3034 results
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
University of UlmTerminatedAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Germany
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
-
PersImmune, IncUniversity of California, San DiegoUnknown
-
Opna-IO LLCCompletedHigh-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)United States
-
Schrödinger, Inc.RecruitingAcute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic SyndromesUnited States
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedHigh Risk MDS or AML PatientsUnited States
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
-
Institute of Hematology & Blood Diseases Hospital...Beijing Health Alliance Charitable FoundationRecruitingLower Risk MDS Per IPSS-RChina
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...United States
-
Central Hospital, Nancy, FranceInserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental...UnknownHigh-risk Myelodysplastic Syndromes With Excess BlastsFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Institut fuer anwendungsorientierte Forschung und...University Medical Center GoettingenCompletedMyelodysplastic Syndromes (MDS) | Chromosmal Aberrations | Karyotype Evolution | Rare Abnormalities | Cytogenetic MonitoringGermany
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Stanford UniversityCelgene CorporationTerminatedLeukemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)United States
-
Radboud University Medical CenterRecruitingMyelodysplastic Syndromes (MDS)Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
-
TakedaWithdrawn
-
TJ Biopharma Co., Ltd.CompletedAcute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)China
-
Prof. Janet DunnKing's College Hospital NHS Trust; University of Manchester; University of Birmingham and other collaboratorsRecruitingMyelodysplastic Syndromes (MDS)United Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
Sunnybrook Health Sciences CentrePrincess Margaret Hospital, Canada; Juravinski Cancer CenterUnknownQuality of Life | Myelodysplastic Syndromes (MDS) | Red Blood Cell (RBC) TransfusionsCanada
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Case Comprehensive Cancer CenterRecruitingMyelodysplastic Syndrome (MDS)United States
-
Novartis PharmaceuticalsCompletedMyelodysplastic Syndrome (MDS)France, Spain, Belgium, Italy, Greece, Hungary, Germany
-
Weill Medical College of Cornell UniversityNovartis PharmaceuticalsCompletedMyelodysplastic Syndrome (MDS)United States
-
Incyte CorporationTerminatedMDS (Myelodysplastic Syndrome)United States
-
Chinese Society of HematologyHarbin Institute of Hematology & OncologyUnknownMyelodysplastic Syndrome (MDS)
-
Asociación Andaluza de Hematología y HemoterapiaCompleted
-
Genzyme, a Sanofi CompanyTerminatedMyelodysplastic Syndrome (MDS)Germany, United Kingdom, France, Netherlands
-
Heinrich-Heine University, DuesseldorfTerminatedMyelodysplastic Syndrome MDSGermany
-
TelikTerminatedMyelodysplastic Syndrome (MDS)United States